long intergenic non-protein coding RNA 640Genealiases: []
Q-omics provides the consensus-scored LINC00640 profile across patient tissues and cancer cell-line models. LINC00640 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC00640 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, LINC00640 RNA expression shows 13,072 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRP, COAD, and ESCA as cancer lineages where LINC00640 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00640 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00640 survival associations across molecular data types. LINC00640 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00640 RNA expression–survival associations across cancer types. High LINC00640 expression shows unfavorable associations in KIRP, KICH, UVM and DLBC, but favorable associations in LUSC and LAML. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC00640 RNA expression.
This table summarizes LINC00640 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00640. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00640 shows lower tumor expression in COAD, BRCA and THCA and higher tumor expression in LUSC, HNSC and BLCA. The COAD box plot shows higher LINC00640 RNA expression in normal versus tumor tissue (log2 FC = −0.175, t-test p < 0.001).
This table shows molecular features associated with LINC00640 in patient tissues and cancer cell lines. In patient samples, LINC00640 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
